Our findings critically highlight the effects of anti–PD-L1/lenalidomide on TAMs as a potential strategy to target the CTCL TME that can be explored for other T cell malignancies, including subtypes of CTCL. Here, CD274 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.